Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5366292 | 0.84 | GAA (0.48) | ALDH1A1KDM4EMAPTPOLBMEN1 | |
| SCHEMBL5357684 | 0.82 | SCN8A (0.48) | ALDH1A1POLBHPGDGAAALB | |
| SCHEMBL711924 | 0.82 | KDM4E (0.59) | ALDH1A1KDM4EMAPTPOLBMEN1 | |
| SCHEMBL20945312 | 0.80 | KDM4E (0.65) | ALDH1A1KDM4EMAPTPOLBMEN1 | |
| SCHEMBL28036174 | 0.79 | HTT (0.54) | ALDH1A1KDM4EMAPTPOLBMEN1 | |
| SCHEMBL2748501 | 0.78 | CTNNB1 (0.54) | ALDH1A1KDM4EMAPTPOLBMEN1 | |
| SCHEMBL5366288 | 0.77 | KDM4E (0.41) | ALDH1A1KDM4EMAPTPOLBMEN1 | |
| SCHEMBL30024982 | 0.76 | ALDH1A1 (0.52) | ALDH1A1KDM4EMAPTPOLBMEN1 | |
| SCHEMBL4759903 | 0.76 | ALDH1A1 (0.52) | ALDH1A1KDM4EMAPTPOLBMEN1 | |
| SCHEMBL23121425 | 0.75 | MAPT (0.51) | ALDH1A1KDM4EMAPTPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663979-B1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-7238714-B2 | Aryl or heteroaryl amide compounds | PFIZER JAPAN, INC. (JP) | 2007-07-03 | — | — | US | disclosed |
| EP-1663979-A1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | BERGMANIS ARIJA A | 2005-11-17 | — | — | US | disclosed |
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | ASKAT INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| WO-2005021508-A1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | HRH2, PTGER1, LTB4R2 | ALDH1A1 860/4885KDM4E 875/4885MAPT 3996/4885 |
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | ALDH1A1 897/4885KDM4E 2282/4885MAPT 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.